“
TL;DR
This retrospective cohort study of sepsis patients from a large critical care database found that intravenous thiamine supplementation was associated with reduced ICU and 28-day mortality and more ventilator-free and vasopressor-free days.
The British Journal of Nutrition · 8 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This retrospective cohort study of sepsis patients from a large critical care database found that intravenous thiamine supplementation was associated with reduced ICU and 28-day mortality and more ventilator-free and vasopressor-free days.
This retrospective cohort study analyzed data from the Medical Information Mart for Intensive Care IV database to investigate thiamine supplementation in adult patients with sepsis. Central results indicate that thiamine use was associated with lower ICU all-cause mortality and improved 28-day mortality (HR 0.82; 95% CI 0.71, 0.94), longer ventilation-free days (coefficient 1.09; 95% CI 0.52, 1.67), and longer vasopressor-free days (coefficient 1.61; 95% CI 1.10, 2.12). Subgroup analysis suggested a beneficial effect in patients with myocardial infarction (HR 0.61; 95% CI 0.44, 0.87). Limitations include the retrospective, single-centre design, lack of data on specific thiamine doses and timing, inability to assess lactate as a mediator, and missing baseline thiamine levels. The findings suggest a potential prognostic benefit, but randomised controlled trials are needed for confirmation.